The Black Legacy Advancement Coalition’s annual Health Is Wealth Detroit returns to Detroit’s Eastern Market on Friday, August 16, 2024, from noon until 9:00 p.m. The event’s purpose is to bring education, joy, healing and […]
FDA declines to approve Lykos’ MDMA-based PTSD drug, requests additional trial
Lykos Therapeutics hit a major roadblock Friday in its bid to bring the first psychedelic-based therapy for post-traumatic stress disorder to market, as U.S. regulators rejected its application and called for additional research. The Food and Drug Administration issued a complete response letter for Lykos’ new drug application for its …
Mind Medicine launches new public offering to raise $75 million
New York-based Mind Medicine (Nasdaq: MNMD) announced a new public offering of roughly 9.2 million shares at $7 each, which is aimed at raising $75 million for the psychedelics company. According to the press release announcing the offering, some investors will be given the option of purchasing about 1.4 million …
Relmada Therapeutics says it has enough cash to get through its milestones
After markets closed on Wednesday, Relmada Therapeutics, Inc. (Nasdaq: RLMD) delivered its financial results for the second quarter ending June 30, 2024. The company does not have revenue to report at this time. Relmada told investors that the net loss for the quarter was $17.8 million, or $0.59 per basic and diluted share, compared …